From the pharmacy of the world to your tender desk.
M Care is an Indian-owned pharmaceutical export house supplying WHO-GMP and EU-GMP medicines, biologicals and surgical consumables to hospitals, importers and government tender desks across the United Kingdom, the GCC, and Africa, with destination-ready dossiers, validated cold-chain, and a single named account manager on every shipment.
Rooted in the world's pharmacy
India supplies ~60% of the world's vaccines and the largest share of quality-assured generics outside the US. That is the manufacturing base we buy against, then QA, dossier and ship on your behalf.
Regulator-ready, destination-first
CTD/eCTD dossiers written for MHRA, EMA, SFDA, MoH-UAE, NAFDAC and the rest of the regulators we ship into, not a generic template repurposed page-by-page.
One named person on every order
No call-centre triage, no vanishing reply chains. Your Mumbai desk knows your molecule, your market, your pack-size preference and your customs broker by name.
Six specialty services. One operational backbone.
Sourcing, regulatory affairs, cold-chain logistics and post-shipment aftercare run through the same team in Mumbai. The number on day-one's quote is the number on day-forty's invoice.
Cold-chain validation
Vaccines, insulins, monoclonal antibodies, blood-derived products. Validated 2–8°C and −25°C lanes. Live temperature telemetry. Excursion CAPA opened pre-dispatch, not after the carton lands.
Cold-chain protocol →Orphan drug supply
Rare-disease medicines into MHRA EAMS, EU compassionate-use, GCC rare-disease formulary and global named-patient access programmes. Eculizumab, ataluren, nusinersen, ivacaftor and the long tail. Single-batch supportable.
Orphan drug route →Government supply services
End-to-end tender response across NUPCO, MoHAP, DHA, SEHA, Kuwait MoH, KIMADIA, JPD Jordan, NHS framework, KEMSA, MSD, NMS, EPSS, FDA Philippines and donor-funded pooled procurement. 45+ countries on file.
Government tenders →Comparator drugs & clinical trials supply
CRO-side comparator sourcing and rescue therapy IMPs for global Phase 2 / 3 trials. GCP-aligned, EU CTR / FDA IND ready, blind-packaging and just-in-time labelling supported. Direct partnerships across ICON, Parexel, IQVIA, PPD, Syneos, Medpace.
Comparator drugs & IMPs →GCC Central Registration
One CTD filing reviewed by a lead Gulf state, mutually recognised across Saudi Arabia, UAE, Kuwait, Qatar, Oman and Bahrain. Dossier authoring with Arabic SmPC and pricing-committee follow-through.
GCC central path →WHO-GMP compliance
Manufacturer-side WHO-GMP audit pack and ongoing site qualification across 80+ partner manufacturing facilities. Site GMP certificates verified, Form 25 / 28 cross-checked, change control on every revision.
Manufacturer audit →From Mumbai, into twenty regulated and emerging markets.
Direct export lanes from our Mumbai dispatch hub to hospitals, importers and tender desks across the UK, the EU, the GCC, Africa and South-East Asia. Every lane is temperature-validated where biologics demand it and documented for the destination regulator.
Eight markets, three continents, one Mumbai desk.
NHS Specials in the UK, BfArM-recognised imports into Germany, GCC ministry-of-health tenders, NAFDAC Nigeria and SAHPRA South Africa. Live regulator dossiers, validated cold-chain lanes from Mumbai, and named procurement bodies on every card.
Built for the contract, not the click.
Pharmaceutical exports don't win or lose on the price column. They win on whether the regulator accepts the dossier, whether the 2–8°C lane held from Mumbai to Mombasa, and whether the invoice, certificate of analysis and pack insert line up, down to the comma, when customs opens the carton.
That is the work nobody sees. It is also the only work that matters. We have built the business around it: direct relationships with WHO-GMP and EU-GMP manufacturers, in-house regulatory affairs, audited logistics partners, and the kind of documentation discipline that turns "maybe next quarter" into "cleared, released, delivered."
- Direct relationships with 80+ WHO-GMP manufacturing sites, no brokered stock, no batch mysteries.
- In-house regulatory affairs: dossier authoring, variations, renewals, destination-regulator liaison.
- Artwork control: destination-market labelling and leaflets prepared before shipment, not after rejection.
- Insurance priced into the unit rate, no claim-time surprises.
Depth where you need it. Breadth where you don't.
The portfolio is built around the disease areas that fill hospital pharmacies and tender desks: oncology, anti-infectives, cardiovascular, CNS, diabetes and critical care. Each area is deep — multiple molecules, multiple strengths, multiple dosage forms, each line traceable to a named manufacturing site.
We also stock the things the catalogue pages rarely mention: cold-chain biologicals, intensive-care paralytics, surgical consumables and the hard-to-source named-patient specials that keep a hospital pharmacy working when the primary supplier has defaulted.
Proof written in shipments, not slogans.
Twenty-plus years of export operations from Mumbai into 45+ markets (M Care Exports Pvt. Ltd., founded 2002). The figures below are drawn from our FY24-25 operational log and audited quality records.
45+ export markets served across the UK, European Union, GCC, East, West, Central, North and Southern Africa, South Asia, Eastern Europe, Caucasus, Central Asia, Latin America and ASEAN — every market on a documented regulatory pathway, every shipment on a country-specific dossier.
18 therapeutic categories, 165,000+ SKU portfolio accessible across 80+ WHO-GMP and EU-GMP manufacturing partners audited and shortlisted against the MHRA, SFDA, MOHAP, NAFDAC and PPB quality frameworks.
One-working-day written quote on every enquiry, with price, availability and regulatory status for the destination country. Three in-market offices — Mumbai, London, Dubai — so the clock never gets in the way of an answer.
Recent shipment patterns. Buyer-confidentiality preserved, numbers attached.
Anonymised case summaries from FY24-25 supply windows. Buyer identities are protected at the customer's request — typical of B2B pharmaceutical procurement where procurement leads avoid public attribution. The workflow framework, the regulatory route and the numerical outcome are accurate to what we ran.
UK Specials importer, docetaxel shortage window. When the licensed-source lead time stretched past six weeks, a Reg. 167 named-patient consignment from one of our Indian WHO-GMP partners closed the gap in 11 days end-to-end — manufacturer-side document pack pre-built (CoA, CoPP, MHRA notification, QP release letter), cold-chain on a pre-qualified BOM-LHR lane, on-arrival logger read-out for the importer's RP.
Gulf hospital network, biological cold-chain. Active-shipper consignment of a temperature-sensitive biological on a 72-hour BOM-DXB lane. Pre-conditioning at the manufacturing-plant cold room, continuous IoT logging in transit, on-arrival CAPA opened pre-dispatch as a precautionary protocol. The full consignment cleared with a logger record showing zero excursions outside the 2-8°C band.
West Africa donor-funded oncology programme. Standing-order supply of a generic chemotherapy line through an NGO procurement partner, against WHO prequalified status and NAFDAC + PPB destination registration. Quarterly shipments under continuous cold-chain where indicated, with batch-level CoA and stability data filed against each consignment.
EU parallel-import licence holder, Article 40 route. Repeat consignment of an EU-GMP capable molecule under Qualified-Person release for a German parallel-import operation. CTD Module 3 stability section harmonised to EMA reduced-temperature data convention; EU-zone batch numbering applied at dispatch; pharmacovigilance routing established before the first carton shipped.
GCC central tender response. 18-day NUPCO biosimilar tender window for a haematology line. CTD dossier harmonised to GHC central registration format; SFDA-domestic stability appendix; Arabic-language SmPC and patient information leaflet attached at submission. Response went on day 14 of the window.
NHS framework shortage, anti-infective Reserve line. Ad-hoc order against an NHS framework gap on a Reserve-tier carbapenem when the EU-approved source had a 4-week stock-out. Manufacturer-side document pack built against an MHRA-licensed importer's specifications; cold-chain not required for this molecule; ground-handled at LHR with same-day onward dispatch to the trust pharmacy.
Buyer references available against signed mutual NDA. Direct customer introduction can be facilitated where a prospective buyer's procurement diligence requires a peer reference, subject to existing customers' written consent.
Tell us which molecule, which market, which volume.
One working day to a written reply with price, availability and regulatory status for your destination. No call-centre triage. No sales funnel. Just a human in Mumbai with the answer.
Request a quote → Browse portfolio